Skip to main content

Advertisement

SpringerLink
Log in

Serum uric acid as a predictor of vascular complications in diabetes: an additional case for neuropathy

  • Letter to the Editor
  • Published:
Acta Diabetologica Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Bjornstad P, Maahs DM, Rivard CJ, Pyle L, Rewers M, Johnson RJ, Snell-Bergeon JK (2014) Serum uric acid predicts vascular complications in adults with type 1 diabetes: the coronary artery calcification in type 1 diabetes study. Acta Diabetol (Epub ahead of print). doi: 10.1007/s00592-014-0611-1

  2. Katsiki N, Papanas N, Fonseca VA, Maltezos E, Mikhailidis DP (2013) Uric acid and diabetes: is there a link? Curr Pharm Des 19:4930–4937. doi:10.2174/1381612811319270016

    Article  PubMed  CAS  Google Scholar 

  3. Papanas N, Katsiki N, Papatheodorou K, Demetriou M, Papazoglou D, Gioka T, Maltezos E (2011) Peripheral neuropathy is associated with increased serum levels of uric acid in type 2 diabetes mellitus. Angiology 62:291–295. doi:10.1177/0003319710394164

    Article  PubMed  CAS  Google Scholar 

  4. Papanas N, Demetriou M, Katsiki N, Papatheodorou K, Papazoglou D, Gioka T, Kotsiou S, Maltezos E, Mikhailidis DP (2011) Increased serum levels of uric acid are associated with sudomotor dysfunction in subjects with type 2 diabetes mellitus. Exp Diabetes Res 2011:346051. doi:10.1155/2011/346051

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  5. Daskalopoulou SS, Tzovaras V, Mikhailidis DP, Elisaf M (2005) Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia. Curr Pharm Des 11:4161–4175. doi:10.2174/138161205774913309

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

K Pafili has no conflicts of interest. N Katsiki has given talks, attended conferences and participated in trials sponsored by Novartis, Pfizer, MSD and Astra Zeneca. DP Mikhailidis has given talks, attended conferences and participated in trials and advisory boards sponsored by MSD, and Genzyme. N Papanas has been an advisory board member of TrigoCare International; has participated in sponsored studies by Novo Nordisk and Novartis; has received honoraria as a speaker for Astra-Zeneca, Eli-Lilly, Novo Nordisk and Pfizer; and attended conferences sponsored by TrigoCare International, Novo Nordisk, Sanofi-Aventis and Pfizer.

Human and animal rights disclosure

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Diabetes Clinic, Second Department of Internal Medicine, University Hospital of Alexandroupolis, Democritus University of Thrace, G. Kondyli 22c, 68100, Alexandroupolis, Greece

    K. Pafili & N. Papanas

  2. Department of Clinical Biochemistry (Vascular Disease Prevention Clinics), Royal Free Hospital Campus, University College London Medical School, University College London (UCL), London, NW3 2QG, UK

    N. Katsiki & D. P. Mikhailidis

Authors
  1. K. Pafili
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N. Katsiki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. P. Mikhailidis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N. Papanas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to N. Papanas.

Additional information

Managed by Massimo Porta.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pafili, K., Katsiki, N., Mikhailidis, D.P. et al. Serum uric acid as a predictor of vascular complications in diabetes: an additional case for neuropathy. Acta Diabetol 51, 893–894 (2014). https://doi.org/10.1007/s00592-014-0631-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00592-014-0631-x

Keywords

Search

Navigation